Navigation Links
First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months
Date:10/18/2011

LONDON, BRUSSELS, SEATTLE and NEW YORK, Oct. 18, 2011 /PRNewswire/ -- First results from a large-scale Phase III trial of RTS,S, published online today in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protection against clinical and severe malaria with an acceptable safety and tolerability profile. The results were announced today at the Malaria Forum hosted by the Bill & Melinda Gates Foundation in Seattle, Washington.

5 to 17 month-old childrenThe trial, conducted at 11 trial sites in seven countries across sub-Saharan Africa, showed that three doses of RTS,S reduced the risk of children experiencing clinical malaria and severe malaria by 56% and 47%, respectively. This analysis was performed on data from the first 6,000 children aged 5 to 17 months, over a 12-month period following vaccination. Clinical malaria results in high fevers and chills. It can rapidly develop into severe malaria, typified by serious effects on the blood, brain, or kidneys that can prove fatal. These first Phase III results are in line with those from previous Phase II studies.

The widespread coverage of insecticide-treated bed nets (75%) in this study indicated that RTS,S can provide protection in addition to that already offered by existing malaria control interventions.

6 to 12 week-old infantsThe trial is ongoing and efficacy and safety results in 6 to 12 week-old infants are expected by the end of 2012. These data will provide an understanding of the efficacy profile of the RTS,S malaria vaccine candidate in this age group, for both clinical and severe malaria.

Combined data in 6 to 12 week-old infants and 5 to 17 month-old children An analysis of severe malaria episodes so far reported in all 15,460 infants and children enrolled in the trial at 6 weeks to 17 months of age has been performed. This analysis showed 35% efficacy over a follow-up period r
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alquest Announced as MedNet Solutions First iMedNet CRO Partner
2. HipSextant™ Navigation System Receives Its First Commercial Use
3. Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES
4. Perrigo Company Will Release First Quarter Fiscal 2012 Results On October 27, 2011
5. Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302
6. Groupe Athena, Inc. Reports Record First Quarter Revenues
7. Microflex XCEED®--First Certified Ergonomic Disposable Examination Glove
8. DMC Cardiovascular Institute Physician is First in Michigan to Use New "Arterial Drill" Catheterization Technique to Remove a Major Blockage
9. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2012 Earnings Release Date and Teleconference
10. Fero Industries Signs First Sucanon® Distribution Agreement for the Middle East
11. voiceTech Launches ServiceLink-Rx, the First Comprehensive Patient Communication Platform for Retail Pharmacies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014 WHEN: Wednesday, October 29, ... registration available at: http://bit.ly/1yStiU9 SPEAKERS: ... and Visionary Innovation Research Group Senior Research ... self-assembling materials, nanobots and flexible electronics are ... transform our lives in the coming decades. ...
(Date:10/22/2014)... 22, 2014  Recently published clinical studies of Stretta ... substantial database of evidence. This data has led to ... therapy for sufferers of refractory GERD. ... supporting Stretta therapy as a safe and effective GERD ... therapy available to nearly 50 million Americans. The new ...
(Date:10/20/2014)... 20 de octubre de 2014  PneumRx, Inc. ... de la pulmonología intervencional, anunció hoy la conclusión ... 3 meses antes de lo programado. El Estudio Clínico ... dispositivo de investigación (IDE) aprobada por la FDA ... de espiral de reducción de volumen pulmonar PneumRx ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... 16, 2011 Reportlinker.com announces that ... is available in its catalogue: ... manufacturing and API sourcing in ... 2011 ...
... -- 3SBio Inc. (NASDAQ: SSRX ) ("3SBio" ... on researching, developing, manufacturing and marketing biopharmaceutical products, today ... and first half ended June 30, 2011. ... Total net revenues increased by 29.0% over the second ...
Cached Medicine Technology:Pharmaceutical Contract Manufacturing and API Sourcing in Central Europe and the Balkan States 2011 2Pharmaceutical Contract Manufacturing and API Sourcing in Central Europe and the Balkan States 2011 3Pharmaceutical Contract Manufacturing and API Sourcing in Central Europe and the Balkan States 2011 4Pharmaceutical Contract Manufacturing and API Sourcing in Central Europe and the Balkan States 2011 53SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 23SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 33SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 43SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 53SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 63SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 73SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 83SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 93SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 103SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 113SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 123SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 133SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 143SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 153SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 163SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 173SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 183SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results 19
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... are only about half as likely as white women to ... indicates, and the racial disparity persists even when donor eggs ... white patients became pregnant after IVF, compared to about 17 ... cycles over two years to tease out the impact of ...
(Date:10/22/2014)... Salamon HealthDay Reporter TUESDAY, ... conventional in vitro fertilization (IVF) -- the incubation of embryos ... a device inside the vagina, new research suggests. Scientists ... called an INVOcell, might sharply cut costs for pricey IVF ... more accessible to those who don,t live near big-city assisted ...
(Date:10/22/2014)... Thompson HealthDay Reporter TUESDAY, Oct. ... with Ebola while working for NBC News in Liberia ... special isolation unit at Nebraska Medical Center in Omaha, where he ... Tuesday. A blood test confirmed by the U.S. Centers for ... home to Providence, R.I., NBC News reported Tuesday night. ...
(Date:10/20/2014)... 2014 Allegheny General Hospital’s (AGH) Cardiovascular ... physicians to repair a damaged mitral valve as the ... system, developed by Abbott Vascular , is designed ... life-threatening condition in which the heart’s mitral valve leaflets ... from the heart’s left ventricle into the left atrium. ...
(Date:10/20/2014)... Columbus, OH (PRWEB) October 20, 2014 ... joined Specialists in Obstetrics & Gynecology of Columbus, Inc., ... specialized women’s healthcare services to more than 100,000 patients ... care though all ages and stages of a women’s ... office locations in Westerville and Dublin. , ...
Breaking Medicine News(10 mins):Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... QUEBEC CITY, May 14 /PRNewswire-FirstCall/ - AEterna ... a global biopharmaceutical company focused on,endocrine therapy ... in the,safety study of the Company,s Phase ... (BPH)., Cetrorelix, a novel investigational luteinizing ...
... 14 /PRNewswire-FirstCall/,-- HeartWare Limited (ASX: HTW) today announced that ... Seventh Annual JMP Securities Research,Conference at 9:30 a.m. PT ... is being held at the Ritz-Carlton, San Francisco May ... at the conference will be,available via a link provided ...
... Johns Hopkins doctors has fine-tuned the dosage and timing ... with strokes caused by bleeding within the brain. The ... Conference in Nice, France, has been shown to dramatically ... lethal subset of stroke. , "We,ve gone from what,s ...
... self esteem, SAUSALITO, Calif., May 14 When Peggy ... afraid to go to school,because she had lost her hair ... of her custom-made hair pieces and invited her and her,mother ... -- and raised the money to pay for it., ...
... Revenue Increase and 45% Profit Growth, RIO DE JANEIRO, Brazil, May 13 ... in Brazil, announced today its consolidated,results for the first quarter 2008., ... 1st QUARTER 2008 Highlights, ... March, 33.3% above the same period last ...
... today signed three bills into law:, Senate Bill ... pharmacies, under the supervision of the State Board of,Pharmacy, ... Under the program, drugs may be returned to an ... their original packaging and the,drug expires no sooner than ...
Cached Medicine News:Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 2Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 3Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 4Health News:AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 5Health News:HeartWare to Present at Seventh Annual JMP Securities Research Conference 2Health News:Researchers fine-tune clot-busting treatment for bleeding in brain 2Health News:Teen Girl Loses Hair But Gains Support 2Health News:Amil Has Strong Growth With High Profitability 2
... is a user friendly computerized medical record ... efficiency and productivity of the practice as ... of documentation. It provides clinical templates for ... complaint. It also contains an exhaustive database ...
... applanation tonometer is designed to fit ... or most "Zeiss" style models. This ... intra-ocular pressure readings. The instrument stays ... and the prism is swung down ...
... first slit lamp truly designed from the ... video imaging. No other slit lamp on ... this exceptional product. The ReSeeVit 5V video ... the market to allow capture of clear, ...
... percent free PSA will help improve the accuracy ... multiple forms in the blood. Most is bound ... early 1990s, it was discovered that measuring the ... help in distinguishing prostate cancer from benign prostate ...
Medicine Products: